Copyright Reports & Markets. All rights reserved.

Global EGFR Mutation Test Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 EGFR Mutation Test Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global EGFR Mutation Test Market Size Growth Rate by Product
      • 1.4.2 DNA Sequencing
      • 1.4.3 Kits
    • 1.5 Market by End User
      • 1.5.1 Global EGFR Mutation Test Market Size Growth Rate by End User
      • 1.5.2 Cancer Hospitals
      • 1.5.3 Clinical Research Institutes
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global EGFR Mutation Test Market Size
      • 2.1.1 Global EGFR Mutation Test Revenue 2014-2025
      • 2.1.2 Global EGFR Mutation Test Sales 2014-2025
    • 2.2 EGFR Mutation Test Growth Rate by Regions
      • 2.2.1 Global EGFR Mutation Test Sales by Regions
      • 2.2.2 Global EGFR Mutation Test Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 EGFR Mutation Test Sales by Manufacturers
      • 3.1.1 EGFR Mutation Test Sales by Manufacturers
      • 3.1.2 EGFR Mutation Test Sales Market Share by Manufacturers
      • 3.1.3 Global EGFR Mutation Test Market Concentration Ratio (CR5 and HHI)
    • 3.2 EGFR Mutation Test Revenue by Manufacturers
      • 3.2.1 EGFR Mutation Test Revenue by Manufacturers (2014-2019)
      • 3.2.2 EGFR Mutation Test Revenue Share by Manufacturers (2014-2019)
    • 3.3 EGFR Mutation Test Price by Manufacturers
    • 3.4 EGFR Mutation Test Manufacturing Base Distribution, Product Types
      • 3.4.1 EGFR Mutation Test Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers EGFR Mutation Test Product Type
      • 3.4.3 Date of International Manufacturers Enter into EGFR Mutation Test Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global EGFR Mutation Test Sales by Product
    • 4.2 Global EGFR Mutation Test Revenue by Product
    • 4.3 EGFR Mutation Test Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global EGFR Mutation Test Breakdown Data by End User

    6 North America

    • 6.1 North America EGFR Mutation Test by Countries
      • 6.1.1 North America EGFR Mutation Test Sales by Countries
      • 6.1.2 North America EGFR Mutation Test Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America EGFR Mutation Test by Product
    • 6.3 North America EGFR Mutation Test by End User

    7 Europe

    • 7.1 Europe EGFR Mutation Test by Countries
      • 7.1.1 Europe EGFR Mutation Test Sales by Countries
      • 7.1.2 Europe EGFR Mutation Test Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe EGFR Mutation Test by Product
    • 7.3 Europe EGFR Mutation Test by End User

    8 Asia Pacific

    • 8.1 Asia Pacific EGFR Mutation Test by Countries
      • 8.1.1 Asia Pacific EGFR Mutation Test Sales by Countries
      • 8.1.2 Asia Pacific EGFR Mutation Test Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific EGFR Mutation Test by Product
    • 8.3 Asia Pacific EGFR Mutation Test by End User

    9 Central & South America

    • 9.1 Central & South America EGFR Mutation Test by Countries
      • 9.1.1 Central & South America EGFR Mutation Test Sales by Countries
      • 9.1.2 Central & South America EGFR Mutation Test Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America EGFR Mutation Test by Product
    • 9.3 Central & South America EGFR Mutation Test by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa EGFR Mutation Test by Countries
      • 10.1.1 Middle East and Africa EGFR Mutation Test Sales by Countries
      • 10.1.2 Middle East and Africa EGFR Mutation Test Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa EGFR Mutation Test by Product
    • 10.3 Middle East and Africa EGFR Mutation Test by End User

    11 Company Profiles

    • 11.1 Abbott
      • 11.1.1 Abbott Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Abbott EGFR Mutation Test Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Abbott EGFR Mutation Test Products Offered
      • 11.1.5 Abbott Recent Development
    • 11.2 Merck
      • 11.2.1 Merck Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Merck EGFR Mutation Test Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Merck EGFR Mutation Test Products Offered
      • 11.2.5 Merck Recent Development
    • 11.3 Thermo Fisher Scientific
      • 11.3.1 Thermo Fisher Scientific Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Thermo Fisher Scientific EGFR Mutation Test Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Thermo Fisher Scientific EGFR Mutation Test Products Offered
      • 11.3.5 Thermo Fisher Scientific Recent Development
    • 11.4 Illumina
      • 11.4.1 Illumina Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Illumina EGFR Mutation Test Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Illumina EGFR Mutation Test Products Offered
      • 11.4.5 Illumina Recent Development
    • 11.5 BioMerieux
      • 11.5.1 BioMerieux Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 BioMerieux EGFR Mutation Test Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 BioMerieux EGFR Mutation Test Products Offered
      • 11.5.5 BioMerieux Recent Development
    • 11.6 QIAGEN
      • 11.6.1 QIAGEN Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 QIAGEN EGFR Mutation Test Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 QIAGEN EGFR Mutation Test Products Offered
      • 11.6.5 QIAGEN Recent Development
    • 11.7 Agilent Technologies
      • 11.7.1 Agilent Technologies Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Agilent Technologies EGFR Mutation Test Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Agilent Technologies EGFR Mutation Test Products Offered
      • 11.7.5 Agilent Technologies Recent Development
    • 11.8 Hologic
      • 11.8.1 Hologic Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Hologic EGFR Mutation Test Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Hologic EGFR Mutation Test Products Offered
      • 11.8.5 Hologic Recent Development
    • 11.9 Novartis
      • 11.9.1 Novartis Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Novartis EGFR Mutation Test Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Novartis EGFR Mutation Test Products Offered
      • 11.9.5 Novartis Recent Development
    • 11.10 Roche
      • 11.10.1 Roche Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Roche EGFR Mutation Test Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Roche EGFR Mutation Test Products Offered
      • 11.10.5 Roche Recent Development
    • 11.11 Genomic Health

    12 Future Forecast

    • 12.1 EGFR Mutation Test Market Forecast by Regions
      • 12.1.1 Global EGFR Mutation Test Sales Forecast by Regions 2019-2025
      • 12.1.2 Global EGFR Mutation Test Revenue Forecast by Regions 2019-2025
    • 12.2 EGFR Mutation Test Market Forecast by Product
      • 12.2.1 Global EGFR Mutation Test Sales Forecast by Product 2019-2025
      • 12.2.2 Global EGFR Mutation Test Revenue Forecast by Product 2019-2025
    • 12.3 EGFR Mutation Test Market Forecast by End User
    • 12.4 North America EGFR Mutation Test Forecast
    • 12.5 Europe EGFR Mutation Test Forecast
    • 12.6 Asia Pacific EGFR Mutation Test Forecast
    • 12.7 Central & South America EGFR Mutation Test Forecast
    • 12.8 Middle East and Africa EGFR Mutation Test Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 EGFR Mutation Test Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Epidermal growth factor receptor (EGFR) is a type of protein, which is located on the surface of human body cells. Any mutation in EGFR gene can lead to various types of cancer. EGFR functions as a biomarker for non-small cell lung cancer (NSCLC) and due to the mutation of EGFR gene a person may suffer from cancer or may have a tumor growth. Tumors with genetically altered EGFR gene are referred to as EGFR-mutated tumors. EGFR mutation is generally observed in NSCLCs, especially in adenocarcinoma tumors. According to the International Association for the Study of Lung Cancer, American Thoracic Society and European Respiratory Society, there are around 50% of surgically resected lung adenocarcinomas in EGFR mutations. These mutations are related to micro papillary predominant subtype and the bronchioloalveolar carcinoma. EGFR biomarker is used in diagnosis of patients with NSCLC. Targeted therapy involving tyrosine kinase inhibitors such as gefitinib and erotinib is used in the treatment of patients with NSCLC. EGFR biomarker detects the presence of specific alterations in EGFR gene, which may lead to the development of tumor.   
      Increasing global prevalence of lung cancer is expected to fuel growth of the global EGFR mutation test market over the forecast period. Increasing adoption of biomarker therapy is also expected to boost growth of the market worldwide over the forecast period.
      The global EGFR Mutation Test market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the EGFR Mutation Test market based on company, product type, end user and key regions.

      This report studies the global market size of EGFR Mutation Test in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of EGFR Mutation Test in these regions.
      This research report categorizes the global EGFR Mutation Test market by top players/brands, region, type and end user. This report also studies the global EGFR Mutation Test market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Abbott
      Merck
      Thermo Fisher Scientific
      Illumina
      BioMerieux
      QIAGEN
      Agilent Technologies
      Hologic
      Novartis
      Roche
      Genomic Health

      Market size by Product
      DNA Sequencing
      Kits
      Market size by End User
      Cancer Hospitals
      Clinical Research Institutes

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global EGFR Mutation Test market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of EGFR Mutation Test market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global EGFR Mutation Test companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of EGFR Mutation Test submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of EGFR Mutation Test are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of EGFR Mutation Test market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now